Biologic therapy for psoriasis: a brief history, II.
This article, the second in a 2-part series, will review interleukin 10 (IL-10) administration, the T-cell receptor mimic peptide, and CTLA4Ig. We also will review 4 of the most promising therapies currently being investigated for the treatment of psoriasis: infliximab, etanercept, efalizumab, and alefacept.
Tutrone
W D
WD
Department of Dermatology, St. Luke's-Roosevelt and Beth Israel Medical Centers, New York, New York 10025, USA.
Kagen
M H
MH
Barbagallo
J
J
Weinberg
J M
JM
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D018849:Controlled Clinical Trials as Topic; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D000069285:Infliximab; D016753:Interleukin-10 / Q000008:administration & dosage; D011379:Prognosis; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D016753:Interleukin-10; D000069285:Infliximab; D000077944:Alefacept; D000068800:Etanercept